Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

Inclusion Criteria: 1. Male patients over the age of 18; 2. The physical condition (PS) score of the Eastern Cooperative Oncology Group (ECOG) is 0, 1, or 2 points; 3. Expected lifespan \>2 years; 4. All newly diagnosed patients with metastatic prostate cancer (mHSPC, metastatic hormone sensitive prostate cancer) diagnosed by PSMA PET/CT, and still present active lesions on PSMA PET/CT after receiving new endocrine therapy; 5. Has not received any other treatment for prostate cancer before; 6. No significant organ dysfunction upon evaluation; 7. Agreed to sign the written consent form for this study, indicating a comprehensive understanding of the purpose and process of this study, and willingness to participate in this study. Exclusion Criteria: 1. A medical history of any other active malignant tumor within 2 years (excluding fully treated basal cell or squamous cell skin cancer, superficial bladder cancer or any other cancer in situ that is currently in complete remission); 2. Prostate biopsy shows sarcomatoid cells, ductal carcinoma, or neuroendocrine cell components; 3. Severe complications, immune suppression, severe mental illness, severe activity restriction, or inability to comply with this study; 4. Currently participating in other clinical trials for prostate cancer; 5. According to the researcher's judgment, there are conditions that are not in line with the best interests of the subjects participating in the study, or may hinder, limit, or interfere with the study protocol.